



Omnichannel Launch Excellence: The pivotal role of **Medical Affairs**

Webinar #3 - THURSDAY 23/5/2024



Ben Harbour VP Global Accounts + 44 7480 37 37 35 ben.harbour@a-cross.com

Stephen Marchant Senior consultant +44 7970 64 30 18 stephen.marchant@a-cross.com

Stephen is a Senior Strategy Consultant with 28 years of experience in Communications and Omnichannel strategy development.

Stephen brings significant experience in developing Omnichannel engagement and communications plans for global pharma, with particular emphasis on pre and peri launch in the medical affairs space.

Fun fact: Stephen is a keen amateur mountaineer.



Ben is VP Global Accounts with over 25 years of experience in Communications and Omnichannel strategy development.

His experience spans the clinical, medical and commercial phases of product development. This end-to-end perspective has helped him to develop a clear understanding of Pharma needs, allowing him to quickly get to the heart of critical scientific and commercial issues

Fun fact: Ben (still) plays rugby for his hometown of York



Ground rules

- This webinar will take around 30 minutes, followed by questions
- You can submit questions at any time via the "Questions" box

- Questions	5
	*
	-
Enter a question for staff]	*
	-

- Please give us your feedback!
 - Right after the webinar a short satisfaction survey will be launched. We would love to know your opinion!








1. Role of Medical Affairs in an Omnichannel world

2. What do HCPs want in the pre launch?


3. Strategic OLE Medical Case study – drive awareness of new biomarker

4. Pre launch KPIs (framework)










Marketing is from Venus and Medical from Mars?



Quick history lesson...







EDUCATE KOLs & HCPs ON THE SCIENCE BEHIND THE BRAND







Quick history lesson...



BUILD RELATIONSHIPS WITH KOLs, BECOME EXPERTS IN THE SCIENCE AND EXPERTS IN COMMUNICATING THE SCIENCE





Translate and contextualize the clinical value of new medicines to stakeholders



INSIGHT GENERATION

EVIDENCE GENERATION

MEDICAL EDUCATION



SCIENTIFIC PLATFORM








Moving from share of voice to **quality of voice**

eMedical Digital Channels (non-exhaustive)








Inertia to omnichannel: the Medical Affairs conundrum....



Protecting credibility, corporate reputation and the interests of patients and other stakeholder by ensuring scientific accuracy, ethical communications and compliance with guidelines <image>


Maximising value by ensuring that medical insight and scientific understanding are leveraged throughout the organisation in order to deliver competitive and commercial advantage








The ideal timeline: where does Medical Affairs support








Importance of being early...







The reality...under 40% initiate their digital OC activities significantly ahead of launch






*Respondents worked on at 1 or more digital launches in the past





The reality...under 40% initiate their digital OC activities significantly ahead of launch







Poll question

Q: What are the bottle necks stopping early involvement?

- Lack of available resource and/or time
- Lack of dedicated budget
- No global support
- Regulatory/Compliance issues in launch countries (understanding or conservative company culture)
- Unsure of customer needs in the pre-launch period







1. Role of Medical Affairs in an Omnichannel world

2. What do HCPs want in the pre launch?

3. Strategic OLE Medical Case study – drive awareness of new biomarker


4. Pre launch KPIs (framework)








What do HCPs want in the pre-launch period?







Engagement model in the pre-launch: the diffusion of innovation




The diffusion of innovation curve E.M Rogers 1962





The diffusion of innovation with EU5 Mixed Specialists

Q: When do you prescribe a new product?




Source: Navigator365[™] EU4+UK Specialists Q3 2023 (n=4031)





What do they want to know about?











How do they want to engage?














(n=4031)




Q: What types of product content do you find most important in a launch situation?


- Better online offerings (16%)
- High cost (30%)
- C-19 impact (18%)

Source: Navigator365[™] EU4+UK Specialists Q3 2023












Source: Navigator365TM EU4+UK Specialists Q3 2023

(n=4031)





Source: Navigator365TM EU4+UK Specialists Q3 2023










Q: What are the key drivers of good customer experience?



Make sure access to MSL and clinical trial content is <u>easy to find</u> and <u>consume</u>! (single click/QR/email call back)

Source: Navigator365[™] EU4+UK Specialists Q3 2023 (n=4031)





Narrow window of opportunity to drive interest and educate

Q: When would you like to engage with <CHANNEL X> for the first time when you want to learn more about a new product?

Preferred time of first engagement with channel

Cardiologist , Dermatologist , Oncologist , Endocrinologist , Hematologist , Pulmonologist , Rheumatologist , Neurologist - France , Germany , Italy , United Kingdom , Spain , United States | N=5635

	International pharma launch symposium	International scientific congress	In-person rep visit	Remote rep	In-person MSL visit	Remote MSL	Pharma enewsletter	Pharma website	Pharma local scientific meeting	Pharma webinar	Medical journal	3rd-party website (Medscape etc.)
12 months before launch	- 4.0 %	• 6.0 %			3.0 %	3.0 %	3.0 %	- 4.0 %	3.0 %	3.0 %	• 8.0 %	3.0 %
6 months before launch	• 10.0 %	. 13.0 %			• 9.0 %	• 9.0 %	• 10.0 %	• 10.0 %	• 9.0 %	• 9.0 %	• 14.0 %	• 8.0 %
3 months before launch	21.0 %	21.0 %			25.0 %	21.0 %	0 22.0 %	0 21.0 %	0 22.0 %	0 22.0 %	26.0 %	0 20.0 %
During Launch	27.0 %	2 2.0 %	3 0.0 %	25.0 %	3 0.0 %	0 24.0 %	29.0 %	3 1.0 %	2 9.0 %	30.0 %	0 24.0 %	0 28.0 %
3 months after launch	16.0 %	1 6.0 %	• 11.0 %	• 13.0 %	15.0 %	14.0 %	• 13.0 %	14.0 %	17.0 %	• 15.0 %	14.0 %	17.0 %
6 months after launch	• 10.0 %	11.0 %	• 7.0 %	• 7.0 %	• 8.0 %	• 9.0 %	• 8.0 %	• 8.0 %	• 11.0 %	• 9.0 %	• 8.0 %	• 10.0 %
12 months after launch	4.0 %	• 6.0 %	2.0 %	2.0 %	3.0 %	3.0 %	3.0 %	3.0 %	4.0 %	3.0 %	4.0 %	4.0 %

Source: Navigator365TM EU4+UK Specialists Q3 2023 (n=4031)



23/05/2024 © Across Health Proprietary and confidential information



27

Summary

Roughly 50:50 between digital/digital mix and F2F in the prelaunch



There is a narrow window of opportunity to engage at launch



Nearly half of your customers want to engage proactively in the pre-launch

> Make sure content and people can be accessed quickly and easily





1. Role of Medical Affairs in an Omnichannel world

2. What do HCPs want in the pre launch?

3. Strategic OLE Medical Case study – drive awareness of new biomarker

4. Pre launch KPIs (framework)










Case study: Strategic Medical launch support





FIC Oncology launch

- Limited footprint within oncology medical community
- Medical identified lack of awareness of new biomarker to identify patient suitability

Prepare the market at launch:


- Awareness and understanding of new biomarker there were 54 new oncology drugs launched in 2023
- Awareness of genomic testing services to identify patient suitability
- Build opt-in and e-permissions to ensure successful commercial (non-personal) engagement at launch



?













POST LAUNCH PRE-LAUNCH PERI-LAUNCH LAUNCH T-12-0 months T-48-24 months T-24–12 months T 0–12 months ACROSS H E A L T H a precision value & health team ACROSS **Omnichannel Launch Excellence:** Medical & Commercial best practices Thursday 27 October 2022 40:42 🜒 🖾 🛃 🏶 🔀





Scientific Platform sits at the core of all communications content

Scientific Platform sits at the core of all launch communication



Compelling, differentiating, robust and **consistent** story is essential when multiple internal stakeholders and external local agencies are involved

- Vocabulary Document what it is (and what it's not)
- Clinical compendium saves time and effort for content and understanding
- Global content creation aligned closely with core launch markets needs and regulatory requirements
- Channel agnostic content easy to adapt to fit with channel





Omnichannel launch excellence needs a 360 customer-centric culture:











Omnichannel launch excellence needs a 360 customer-centric culture:








Omnichannel launch excellence needs a 360 customer-centric culture:








Omnichannel launch excellence needs a 360 customer-centric culture:







Omnichannel launch excellence needs a 360 customer-centric culture:









Congress attendance















Source: Navigator365TM EU4+UK Specialists Q3 2023



(n=4831)

23/05/2024 © Across Health Proprietary and confidential information






Source: Navigator365[™] EU4+UK Specialists Q3 2023 (n=4031)



23/05/2024 © Across Health Proprietary and confidential information







- Attended symposiaWatched webinar
- Previously open emails
- Previously open email
- ✓ 3 previous questions























Medical Affairs input and investment critical to launch preparation and success



OUTCOMES:

- Increased opt-in
- Appropriate Medical insights to drive commercial plan:
 - Challenges and bottlenecks which need to be solved at launch to improve patient outcomes
 - Understanding of HCP educational needs and behaviours to formulate a commercial segmentation

Feedback first

Established





QUALITATIVE	CHANNEL (DIRECT)	BRAND (INDIRECT)
QUANTITATIVE		






QUALITATIVE	CHANNEL (DIRECT)	BRAND (INDIRECT)		EM Open rate
			The foundation of any	Conversio
QUANTITATIVE	DID WE CONNECT?		campaign – are we	Opt-out r
			generating the right	Click-thro
			number of touchpoints to achieve our	Delivery r
			behavioural objectives?	Subscribe

EMAIL	WEB	MSL FIELD	
Open rate	# of visitors	Calls	
Conversion rate	Consent capture	Meetings attended	
Opt-out rate	% page scroll	EVENT	
Click-through rate	Time spent on site	# invited	
Delivery rate	Downloads	# invite accepted	
Subscribers	Opt-ins	% attended	









Is our content appreciated and valuable for our audience?






Would you recommend our website to a colleague?

a confirm







10



Do we make an impact and are we changing audience's mindset?

- Impact of educational event on future clinical practice
- Intent to apply learning to future clinical practice
- □ Intent to prescribe (Post launch)
- □ NPS^{*} of company
- □ NPS of educational campaign











ROI – Did we increase awareness, reach & impact? □ Request for information

- Opt-in rates
- Referral to genomic testing centers (post launch)










Pre-launch NPS and high channel mix is a direct predictor for a successful launch*

*No More Surprises: Understanding Predictors of Launch Success IQVIA White Paper



23/05/2024 © Across Health Proprietary and confidential information





The **first 6 months** of launch predicts the success of the brand









Question time!

Want to know more? Join us on our upcoming webinars



UPCOMING

- Omnichannel upskilling: Transforming customeroriented teams into customer engagement experts THURSDAY, JUNE 13TH 16H CET
- Omnichannel transformation: Where's the industry at? (Maturometer[™] 2024) TUESDAY, OCT 1ST 16H CET





The 2024 survey is now open... (We need your input!)



www.across.health/maturometer2024







Right after the webinar, a short satisfaction survey will be launched. We would love to know your opinion!







Omnichannel Launch Excellence as part of our end-to-end omnichannel consulting services - built on a robust evidence base







Talk to us about how our strategic consulting services – fuelled by the latest HCP and industry insights pulled from our Navigator365™ and Maturometer™ research – can help accelerate your journey towards delivering an unparalleled omnichannel customer experience.







https://www.across.health